SCR 73 is a Senate Concurrent Resolution that proclaims the week of June 16–22, 2025, as Familial Adenomatous Polyposis (FAP) Awareness Week in California. The resolution summarizes clinical facts about APC-associated polyposis and its risks, encourages Californians to gather family health histories and discuss them with their health care providers, and cites Stanford University programs as partners in raising awareness.
The resolution is ceremonial: it does not create rights, duties, funding, or regulatory changes. Its practical effect is awareness-raising—potentially increasing demand for genetic counseling, testing, and earlier colorectal screening—without providing an implementation or funding mechanism.
That combination creates implementation and equity questions for clinicians, health systems, and payors who may see increased service demand following the awareness campaign.
At a Glance
What It Does
Proclaims June 16–22, 2025 as Familial Adenomatous Polyposis Awareness Week in California, lists clinical facts about FAP and AFAP, and encourages residents to collect family health histories and consult health care providers about genetic counseling or testing. It names Stanford University departments as participants in awareness efforts and directs the Secretary of the Senate to distribute copies of the resolution.
Who It Affects
Individuals with hereditary colorectal cancer risk, genetic counselors, gastroenterology and oncology clinics, academic centers cited as partners, public health communicators, and health insurers who may face increased requests for testing or screening. State agencies and the Legislature have no new regulatory responsibilities from the resolution itself.
Why It Matters
The measure elevates a rare-but-high-risk hereditary condition into public-health messaging in California, which can change clinical demand patterns and inform referral and testing behavior. Because the resolution contains no funding or programmatic direction, affected actors must absorb any practical consequences—such as increased appointments or lab testing—within existing resources.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SCR 73 is a ceremonial declaration focused on Familial Adenomatous Polyposis (FAP) and its attenuated form (AFAP). The resolution compiles clinical statements—APC gene mutations cause hundreds of colon polyps, FAP typically leads to cancer around age 39 if untreated, AFAP presents later with fewer polyps and average cancer diagnosis around 55—and uses those facts to justify designating a one-week awareness period.
The resolution explicitly encourages people who have a first-degree relative with FAP or AFAP to gather their family health history and discuss it with a health care provider to determine whether genetic counseling or testing is appropriate. It highlights that undiagnosed cases raise the risk of cancers beyond the colon (stomach, small intestine, liver, brain, thyroid, pancreas) and notes noncancer manifestations such as osteomas and desmoid tumors.Practically, SCR 73 does not create programs, authorize spending, or change medical standards of care.
It names Stanford University’s Department of Health Policy, Genetics and Genomics Program, and Cancer Center as partners for awareness activities and asks the Secretary of the Senate to transmit copies to the author for distribution. That means awareness activity may be concentrated around academic and advocacy networks rather than coordinated statewide public-health implementation.The most consequential outcome is operational: increased public awareness often produces more patient inquiries, referrals to genetic counseling, and requests for earlier or additional colorectal screening.
Because the resolution contains no mandate to expand capacity, laboratories, clinics, insurers, and safety-net providers will have to meet any increased demand with existing budgets and workflows, raising questions about access and equitable uptake of recommended testing and preventive measures.
The Five Things You Need to Know
The resolution proclaims June 16–22, 2025, inclusive, as Familial Adenomatous Polyposis Awareness Week in California.
It compiles clinical details from the bill text: APC gene mutations cause FAP, untreated FAP typically leads to colorectal cancer by about age 39, and AFAP has an average cancer diagnosis age of about 55.
The measure explicitly encourages Californians with affected first‑degree relatives to gather family health history and discuss genetic counseling or testing with a health care provider.
Stanford University’s Department of Health Policy, Genetics and Genomics Program, and Cancer Center are named as participants in awareness activities called out in the text.
The resolution is ceremonial and nonbinding: it does not authorize funding, create regulatory obligations, or change medical standards; it directs the Secretary of the Senate to transmit copies to the author for distribution.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Clinical context and justification for awareness
The resolution’s WHEREAS clauses list medical facts the Legislature uses to justify the awareness week: APC-associated polyposis causes high polyp burden, FAP and AFAP differ in onset and typical cancer age, and the conditions increase risk for several non-colorectal cancers and tumors. Those statements do the heavy lifting of policy justification: they frame FAP and AFAP as preventable or manageable public-health concerns if identified early. For practitioners, the value of this section is political and communicative—legislative acknowledgement can amplify clinical messaging—but it imposes no clinical standards.
Designation of awareness week and public encouragement
This part formally proclaims June 16–22, 2025 as Familial Adenomatous Polyposis Awareness Week and includes a call to action: Californians are encouraged to gather family health history and share it with providers to consider genetic counseling or testing. The proclamation is declaratory only; it expresses legislative intent to raise awareness rather than directing agencies to act or obligating healthcare payors to cover services.
Identification of Stanford programs as awareness partners
The resolution singles out Stanford University’s Department of Health Policy, Genetics and Genomics Program, and Cancer Center as entities joining the Legislature in raising awareness. Naming specific academic programs focuses outreach through established research and clinical channels, which can increase visibility among clinicians and patients connected to those networks but may concentrate activity regionally rather than statewide.
Transmission of the resolution
The final operative line directs the Secretary of the Senate to transmit copies of the resolution to the author for distribution. This is a standard, low-cost administrative step that enables the author and their designees, including partner organizations, to publicize the proclamation. It does not obligate any state agency to implement programs or allocate resources.
No fiscal committee referral or stated fiscal effect
The digest includes a fiscal committee entry reading 'NO,' reflecting that the resolution carries no identified fiscal impact and therefore was not referred for fiscal review. For administrators and budget officers, this signals that the resolution does not trigger budgetary commitments, though downstream service demand could produce indirect costs for health systems and insurers.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals at risk for FAP/AFAP — The resolution raises public awareness that may prompt earlier family-history gathering, referral, and preventive screening, increasing the chance of early detection for people with hereditary risk.
- Genetic counselors and specialty clinics — Increased awareness tends to raise referral volumes and visibility for genetic counseling programs and surgical/gastroenterology services that manage FAP.
- Academic centers and research programs (e.g., Stanford) — Named participation provides visibility and an outreach platform that can support recruitment for research, educational events, and fundraising tied to hereditary cancer work.
- Patient advocacy groups focused on hereditary cancer — The legislative proclamation offers a moment for outreach, membership drives, and public education campaigns to reach new audiences.
Who Bears the Cost
- Health care providers and specialty clinics — They may face higher volumes of patient inquiries, genetic counseling consultations, and surveillance procedures without additional funding or staff.
- Clinical laboratories and genetic-testing programs — Increased demand for testing could strain lab capacity and create logistical or turnaround-time pressures; costs will be borne by patients, insurers, or programs depending on coverage.
- Insurers and payors — If awareness produces more covered genetic tests and earlier surveillance, payors may see an uptick in claims; decisions about coverage criteria will determine financial exposure.
- State and local public-health communicators — Any expectation to amplify or coordinate messaging will fall within existing communications budgets and priorities unless additional resources are provided.
- Safety-net providers and community clinics — These providers may shoulder disproportionate capacity and cost burdens if awareness activities increase demand among populations with limited insurance or access.
Key Issues
The Core Tension
The central tension is between symbolic, low-cost public-health advocacy and the real-world resource implications of successful awareness: the Legislature can cheaply increase demand for genetic services and early screening through proclamation, but without funding or implementation planning it risks creating unmet demand and widening access gaps among populations least able to obtain genetic counseling or pay for testing.
SCR 73 is purely symbolic and contains no funding, enforcement language, or programmatic directives. That means the resolution can raise awareness without accompanying resources to expand genetic counseling, testing, or screening capacity.
The likely result is a spike in demand routed into existing systems—specialty clinics, labs, and insurers—that must absorb increased volume under current staffing and payment arrangements. That dynamic creates particular strain for safety-net providers and labs with limited surge capacity.
The resolution also centralizes outreach by naming a specific academic partner. While that can expedite high-quality messaging, it risks uneven geographic reach and may inadvertently privilege institutions with existing resources.
Finally, the clinical statements included in the preamble (average ages of cancer onset, multisite risk) are accurate but simplified; the resolution does not provide clinical guidance on who should be tested, when to begin surveillance, or how screening should be funded—leaving those important implementation questions to clinicians, payors, and public-health agencies outside the legislative text.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.